PLRX Insider Trading Activity and SEC Form 4 Filings
PLRX insider trading summary
Over the past 12 months, insiders at Pliant Therapeutics, Inc. (PLRX) reported 4 sales worth $164K by 4 insiders and no open-market purchases on SEC Form 4. Net insider selling was $164K.
Latest PLRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 20, 2026 | Bernard Coulie | President and CEO | Sell | $114K (89,375 @ $1.28) |
| Jan 20, 2026 | Lily Cheung | Chief Human Resource Officer | Sell | $10K (7,534 @ $1.28) |
| Jan 20, 2026 | Keith Lamont Cummings | Chief Financial Officer | Sell | $31K (24,002 @ $1.28) |
| Jan 20, 2026 | Minnie Kuo | Chief Operating Officer | Sell | $9K (6,917 @ $1.28) |
| Jan 22, 2025 | Mike Ouimette | General Counsel & Corp. Sec'y | Sell | $112K (10,230 @ $10.99) |
| Jan 17, 2025 | Lily Cheung | Chief Human Resource Officer | Sell | $42K (3,740 @ $11.20) |
| Jan 17, 2025 | Bernard Coulie | President and CEO | Sell | $587K (52,419 @ $11.20) |
| Jan 17, 2025 | Mike Ouimette | General Counsel & Corp. Sec'y | Sell | $149K (13,270 @ $11.20) |
| Jan 17, 2025 | Eric Lefebvre | Chief Medical Officer | Sell | $207K (18,478 @ $11.20) |
| Jan 17, 2025 | Keith Lamont Cummings | Chief Financial Officer | Sell | $226K (20,148 @ $11.20) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.